Prophylactic clarithromycin to treat mycobacterium avium in HIV patients receiving
zidovudine may significantly increase mortality by suppressing lymphopoiesis and
hematopoiesis.
Freund YR, Dousman L, Mohagheghpour N.  
Int Immunopharmacol 2002 Sep;2(10):1465-75
Abstract 

Higher levels of Zidovudine resistant HIV in the colon compared to blood and other gastrointestinal compartments in HIV infection. van Marle G, Church DL, Nunweiler KD,  et al Retrovirology. 2010 Sep 13;7(1):74 Abstract Rate of Accumulation of Thymidine Analogue Mutations in Patients Continuing to Receive Virologically Failing Regimens Containing Zidovudine or Stavudine: Implications for Antiretroviral Therapy Programs in Resource-Limited Settings. Cozzi-Lepri A, Phillips AN, Martinez-Picado J,  et al J Infect Dis. 2009 Jul 15. Abstract FULL TEXT ARTICLE N348I in the Connection Domain of HIV-1 Reverse Transcriptase Confers Zidovudine and Nevirapine Resistance. Yap SH, Sheen CW, Fahey J, et al  PLoS Med. 2007 Dec 1;4(12):e335 Paper   Mechanisms by which G333D in HIV-1 Reverse Transcriptase Inhibitors Facilitates Dual Resistance to Zidovudine and Lamivudine Zelina S, Sheen CW, Radzio J, et al Antimicrob Agents Chemother. 2007 Oct 29; Abstract   A WEEK-IN-REVIEW FEATURED REPORT FULL-TEXT ARTICLE Why Do HIV-1 and HIV-2 Use Different Pathways to Develop AZT Resistance? Boyer PL, Sarafianos SG, Clark PK, et al PLoS Pathog. 2006 Feb 17;2(2):e10 Paper   Effect of the Q207D Mutation in HIV Type 1 Reverse Transcriptase on Zidovudine Susceptibility and Replicative Fitness. Lu J, Whitcomb J, Kuritzkes DR. J Acquir Immune Defic Syndr. 2005 Sep 1;40(1):20-23. Abstract   Natural resistance of human immunodeficiency virus type 2 to zidovudine. Reid P, Macinnes H, Cong ME, et al  Virology. 2005 Jun 5;336(2):251-64. Abstract   Primer unblocking by HIV-1 reverse transcriptase and resistance to nucleoside RT inhibitors (NRTIs). Goldschmidt V, Marquet R. Int J Biochem Cell Biol. 2004 Sep;36(9):1687-705. Abstract   Rate of Thymidine Analogue Resistance Mutation Accumulation With Zidovudine- or Stavudine-Based Regimens. For the Adult ACTG Protocol 306 370 Teams.  J Acquir Immune Defic Syndr. 2004 Apr 20;36(1):600-603. Abstract   FULL-TEXT PDF ARTICLE Nonnucleoside inhibitors of HIV-1 reverse transcriptase inhibit phosphorolysis and resensitize the 3'-azido-3'-deoxythymidine (AZT)-resistant polymerase to AZTTP. Odriozola L, Cruchaga C, Andreola M, et al. J Biol Chem. 2003 Aug 13 Paper

Correlation of Phenotypic Zidovudine Resistance with Mutational Patterns in the
Reverse Transcriptase of Human Immunodeficiency Virus Type 1: Interpretation
of Established Mutations and Characterization of New Polymorphisms at Codons
208, 211, and 214.
Sturmer M, Staszewski S, Doerr HW, et al.
Antimicrob Agents Chemother 2003 Jan;47(1):54-61
Abstract 

Sustained high proportion of zidovudine-resistant HIV variants despite prolonged
substitution of zidovudine by other nucleoside reverse transcriptase inhibitors.
Belec L, Legoff J, Si-Mohat al.
J Med Virol 2002 Sep;68(1):1-6
Abstract 
 

Carrier rate of zidovudine-resistant HIV-1: the impact of failing therapy on transmission of resistant strains. Goudsmit J, Weverling GJ, van Der Hoek L, et al AIDS 2001 Nov 23;15(17):2293-2301 Abstract

Tenofovir, Adefovir, and Zidovudine Susceptibilities of Primary Human  immunodeficiency Virus Type 1 Isolates with Non-B Subtypes or Nucleoside Resistance. Palmer S, Margot N, Gilbert H, et al. AIDS Res Hum Retroviruses 2001 Aug 10;17(12):1167-1173 Abstract

FULL-TEXT ARTICLE Delavirdine in Combination with Zidovudine in Treatment of Human Immunodeficiency Virus Type 1-Infected Patients: Evaluation of Efficacy and Emergence of Viral Resistance in a Randomized, Comparative Phase III Trial Joly V, Moroni M, Concia E, et al. Antimicrob Agents Chemother 2000 Nov;44(11):3155-3157 Paper